

the actual bias of the coin equals the observed proportion of heads. A fully Bayesian analysis, accounting for the fact that the amount of bias is unknown, might even mildly favor "no bias"!

I was teaching a unit on Bayesian inference when the discovery of a possible planet around PSR 1829-10 mentioned in Seife's article was announced. I noticed that the period claimed for the planet was suspiciously close to a low harmonic of Earth's orbital period. A simple Bayesian analysis for my class (2) indicated the truth: it was highly probable that the result was spurious. Let this be a lesson!

William H. Jefferys

Department of Astronomy, University of Texas,  
Austin, TX 78712, USA. E-mail: bill@astro.as.  
utexas.edu

#### References

1. J. O. Berger and M. Delampady, *Stat. Sci.* **2**, 317 (1987).
2. W. H. Jefferys and J. O. Berger, *Am. Sci.* **80**, 64 (1992).

### Examining Priorities for a Primate Genome Project

We agree with the premise of Edwin H. McConkey, Agit Varki, and cosignatories that "[a] primate genome project deserves high priority" in the U.S. biomedical research enterprise (Letters, 25 Aug., p. 1295), but we

disagree with their selection of the chimpanzee as the focus for these efforts, and with the recommendation to commit resources to genome sequencing at this time.

The choice of which primate to select for this \$100 million project should be driven by the goals of the National Institutes of Health's (NIH) mission to promote human health through research. Although chimpanzees have been vital for many advances in biomedical research and continue to serve critical research needs, they are not a commonly used model. With fewer

than 1000 federally supported chimpanzees in U.S. research colonies and a moratorium on breeding, the chimpanzee is unlikely to become a widely used animal model. Because it is not practical to use chimpanzees for most research purposes, a focus on chimpanzee genomics would have little impact on future opportunities and progress in biomedical research.

The initial plan to sequence the human genome was deferred until a detailed gene map was constructed, and we contend that constructing gene maps of nonhuman pri-

mates deserves priority over sequencing, for the same scientific and cost-benefit reasons. Furthermore, the resources should be devoted to those species that are most widely used as primate models for genetic research on human diseases and for which extensive physiological data are available—namely, baboons and rhesus macaques.

Another high priority for a primate genome project would be research on gene expression. To the extent that this research is supported by the NIH, the driving force behind it should be to develop a better understanding of biological



A candidate for genome analysis.

CREDIT: J. ROGERS

We are experts in  
connective tissue  
research.

We Desire to Cooperate with You  
in Your Research and Diagnostic Fields.

### Diabetic Nephropathy

**NEW** Urinary type-IV collagen kit  
Approved by Japanese Government as *In Vitro* Diagnostics.

### Rheumatoid Arthritis

**NEW** MMP-3 kit  
Approved by Japanese Government as *In Vitro* Diagnostics.

### Cancer Invasion & Metastasis

#### MONOCLONAL ANTIBODIES

**NEW** For Cathepsin series;  
Cathepsin L2, Cathepsin Z, Cathepsin F, Cathepsin K, and others.

**NEW** For MMPs and TIMPs;  
TIMP-4, MMP-20, MMP-13, MT1-MMP, MT2-MMP, MT3-MMP  
MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, TIMP-1, TIMP-2, TIMP-3

#### ENZYME IMMUNOASSAYS (Kits & \*Custom Assays)

MMP-1/TIMP-1 complex kit, MMP-3/TIMP-1 complex kit,  
MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2, \*MMP-7, \*MMP-8, \*MMP-13, \*Rabbit MMP3

For more information at <http://www.fuji-chemi.co.jp>



**FUJI CHEMICAL INDUSTRIES, LTD.**

530 Chokeiji, Takaoka, Toyama 933-8511, Japan

FAX: +81-766-26-4437 E-mail: msts@fuji-chemi.co.jp

Circle No. 15 on Readers' Service Card

mechanisms that differentiate healthy from disease states. In that regard, those nonhuman primate species that are used extensively as models in biomedical research offer many more opportunities for scientific advancement through gene expression studies than do chimpanzees.

Regarding the goal of defining the genetic changes that underlie human uniqueness, it is not only peripheral to the NIH mission but also is not well served by a sequencing-first approach. Most sequence differences between humans and chimpanzees will be functionally neutral, and simple comparison of sequences will not identify the few functional changes among the large number of neutral substitutions.

We urge the National Human Genome Research Institute (NHGRI) and the National Center for Research Resources to consider carefully the scientific value of sequencing the chimpanzee genome by comparison with investing equal resources in supporting gene expression research and developing detailed gene maps of nonhuman primates that are extensively used in biomedical research. The potential health benefits of these research activities in well-characterized, widely-used Old World monkey models will be much greater than those obtained from sequencing the chimpanzee genome.

**John L. VandeBerg**

Southwest Regional Primate Research Center, San Antonio, TX 78245, USA. E-mail: jlv@sfrb.org

**Sarah Williams-Blangero**

Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX 78245, USA. E-mail: sarah@darwin.sfrb.org

**Bennett Dyke**

**Jeffrey Rogers**

Genetics Group, Southwest Regional Primate Research Center. E-mail: bdyke@darwin.sfrb.org and jrogers@darwin.sfrb.org

### Response

In our original letter we presented the arguments in favor of a primate genome project and suggested that the project should focus both on the chimpanzee, because it is our closest evolutionary relative, and on one of the well-studied Old World monkeys, which would be more suitable for experimental purposes and for studies of gene expression. Thus, we have a substantial area of agreement with VandeBerg and colleagues. However, we disagree with their statement that "a focus on chimpanzee genomics would have little impact on future opportunities and progress in biomedical research." The potential relevance of chimpanzee genome data for understanding such diseases as AIDS, Alzheimer's, malaria, and others has been presented elsewhere (1).

VandeBerg and colleagues also say that "the goal of defining the genetic changes

that underlie human uniqueness [is] peripheral to the NIH mission." This implies that the genes involved in human uniqueness are never involved with human disease, a highly unlikely assumption. For example, genes that underlie bipedal locomotion may be involved in many malfunctions of the musculoskeletal system, and genes that mediate specific aspects of human cognition are likely to be involved in mental illness. In general, it will not be possible to separate genomic information relevant to human evolution from that relevant to human disease. The close similarity of the chimpanzee and human genomes also increases the likelihood of finding disease-related differences quickly. Furthermore, any genomic differences found between Old World monkeys and humans will be easier to interpret if the corresponding regions of the chimpanzee genome are also available.

We did not mean to imply that a primate genome project should begin with or be limited to total sequencing of the chimpanzee genome. Our hope is that NHGRI (and other funding agencies in the United States and elsewhere) will consider a variety of approaches to primate genomics that may advance our understanding of human genetic function in health and disease. Suggestions such as those made by VandeBerg and colleagues will contribute to the decisions that must be made by the administrators of the funding agencies. The main purpose of our letter was to emphasize the need to give high priority to genomic studies on primates, rather than limiting comparative genomics to nonprimate mammals in the immediate future.

**Edwin H. McConkey**

Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA. E-mail: mcconkey@stripe.colorado.edu

**Ajit Varki**

Department of Medicine, Glycobiology Research and Training Center, University of California, San Diego, La Jolla, CA 92093, USA. E-mail: avarki@ucsd.edu

### References

1. A. Varki, *Genome Res.* 10, 1065 (2000).

### Transgenic Crops in China


In his News Focus report entitled "Asia gets a taste of genetic food fights" (25 Aug., p. 1279), Dennis Normile states that in China there are four transgenic crops (six varieties) in commercial cultivation and five transgenic crops in field trials or in development, but this is not so.



In China, the study of transgenic crops began in the early 1990s; the first field trial of a transgenic crop occurred in 1994. Up to now, there are three transgenic crops (cotton, tomato, sweet pepper) and 12 varieties in commercial cultivation (1), eight of which are transgenic cotton varieties (2). There are seven crops




## The M@X Dimension





**GATC Biotech AG**  
 Jakob-Stadler-Platz 7  
 D-78467 Konstanz  
 Fon +49 (0) 7531 81 60 0  
 Fax +49 (0) 7531 81 60 81  
 service@gatc-biotech.com  
 www.gatc-biotech.com

The transformation was successful!  
**GATC GmbH is now the new GATC Biotech AG.**

Circle No. 17 on Readers' Service Card

# Discover it